Metraipolis › archive › dc_059b123124cd

Envonalkib Versus Crizotinib in Treatment-Naive ALK -Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III… — Europe PMC PMID:42830869

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42830869
DOI
10.1002/mco2.70998
License (as archived)
solo-consultazione
Archived
2026-10-07T14:08:47.197Z
SHA-256 of the archived text
d6043aa8a31bc03e53f4d20a0b3b693538b781de318aa0e90c8576565eee24c3
Stable URL of this page
https://metraipolis.com/documento/dc_059b123124cd

How to cite

Envonalkib Versus Crizotinib in Treatment-Naive ALK -Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III… — Europe PMC PMID:42830869 — Europe PMC (en), https://europepmc.org/article/MED/42830869 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_059b123124cd (Metraipolis archive dc_059b123124cd, sha256 d6043aa8a31bc03e53f4d20a0b3b693538b781de318aa0e90c8576565eee24c3)
BibTeX
@misc{dc059b123124cd,
  title = {Envonalkib Versus Crizotinib in Treatment-Naive ALK -Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III… — Europe PMC PMID:42830869},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42830869},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_059b123124cd; sha256 d6043aa8a31bc03e53f4d20a0b3b693538b781de318aa0e90c8576565eee24c3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42830869. Agents can read the archived copy with the MCP tool read_document.